FDA Import Refusal SCS-4140684-1/20002/1A — Revance Therapeutics, Inc
The FDA refused shipment SCS-4140684-1/20002/1A from Revance Therapeutics, Inc (United States) on Jul 8, 2026. The refused product falls under Drugs and Biologics — DAXIBOTULINUMTOXINA-LANM. Cited charge: 179 This firm has 3 other import refusals on record.
Refusal details
- Date
- Jul 8, 2026
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 58PCY04 DAXIBOTULINUMTOXINA-LANM
- Charges
- 179